FDA Approves Autoinjector Pen for Humira Biosimilar, Cyltezo FDA Approves Autoinjector Pen for Humira Biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 22, 2023 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news
US FDA Approves the Cyltezo Pen, a New Autoinjector Option, Ahead of July 1 Commercial Launch
RIDGEFIELD, Conn., May 22, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the Cyltezo® Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 22, 2023 Category: Drugs & Pharmacology Source Type: news
What To Expect After The Failed AbbVie Drug Sales (NYSE:ABBV)
On April 27, 2023, AbbVie (NYSE:ABBV) released its Q1 2023 financial results. In recent quarters, sales of the company's products have shown mixed dynamics, which led to falling short of Wall Street analysts' expectations. So, AbbVie's revenue amounted to $12,225 million in the first three months…#abbvie #richardgonzalez #humira #tnf #amjevita #amgen #amgn #fda #boehringeringelheim #skyriziandrinvoq (Source: Reuters: Health)
Source: Reuters: Health - April 30, 2023 Category: Consumer Health News Source Type: news
AbbVie's Humira Downfall Is Swift As Biosimilars Hammer Away At Sales
stock crumbled Thursday after the first approved biosimilar copycat to launch in the U.S. hammered away at Humira's legendary sales. X Though Amgen's (AMGN) biosimilar, dubbed Amjevita, launched halfway through the first quarter, global sales of immunology blockbuster Humira slumped more than 25%…#humira #amgen #amgn #rickgonzalez #abbvie #rinvoq #leebrown #thirdbridge #robmichael #marketsmithcom (Source: Reuters: Health)
Source: Reuters: Health - April 29, 2023 Category: Consumer Health News Source Type: news
Adalimumab + Methotrexate Beneficial for Pediatric Crohn Disease
THURSDAY, April 27, 2023 -- For pediatric Crohn disease (PCD) patients, treatment with methotrexate combined with adalimumab, but not infliximab, is associated with a reduction in treatment failure, according to a study published online March 31 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 27, 2023 Category: Pharmaceuticals Source Type: news
With Humira exclusivity gone, AbbVie struggles in the first quarter
Global sales of AbbVie's flagship arthritis drug fell more than 25% after rival drugmakers were allowed to sell nearly identical products. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 27, 2023 Category: American Health Authors: Ben Miller Source Type: news
AbbVie: The Tsunami Heading Towards Investors
AbbVie (NYSE:ABBV) focuses on discovering, developing, and marketing branded therapeutics protected by intellectual property rights, allowing it to command higher prices and margins. However, once the exclusivity expires (usually after 15-20 years), other companies can produce and sell generic…#abbv #abbottlaboratories #abt #humira #onceamgen #amgn #amgevita #fda #amgen #mylan (Source: Reuters: Health)
Source: Reuters: Health - April 14, 2023 Category: Consumer Health News Source Type: news
Pediatric Crohn's: Adalimumab+Methotrexate Offers Strong Benefit Pediatric Crohn's: Adalimumab+Methotrexate Offers Strong Benefit
A landmark trial suggests adding low-dose methotrexate should be strongly considered in children with Crohn ' s disease who are starting adalimumab.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - April 14, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news
Psoriasis Highlights From AAD 2023 Psoriasis Highlights From AAD 2023
Highlights in psoriasis and related disorders from AAD 2023 include data on secukinumab, adalimumab, and deucravacitinib, as reported by Dr Joel Gelfand.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 10, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar
The agency approved a higher concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - March 27, 2023 Category: Pediatrics Tags: Rheumatology News Alert Source Type: news
Sandoz Receives US FDA Approval for Biosimilar Hyrimoz (adalimumab-adaz) High-Concentration Formulation
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®*
With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 21, 2023 Category: Drugs & Pharmacology Source Type: news
Should You Buy The Botox Maker Over Johnson & Johnson Stock?
We believe that AbbVie stock (NYSE: ABBV) is currently a better pick than its industry peer, Johnson & Johnson stock (NYSE: JNJ), given its better growth prospects. Although AbbVie is trading at 4.8x trailing revenues compared to 4.2x for J&J, this gap in valuation looks justified, given the…#abbvie #johnsonjohnson #jnj #remicade #allergan #humira #crohn #botox #rinvoq #abbvierevenue (Source: Reuters: Health)
Source: Reuters: Health - March 21, 2023 Category: Consumer Health News Source Type: news
TREMFYA ® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
SPRING HOUSE, PENNSYLVANIA, March 17, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA® (guselkumab) was associated with greater treatment persistencea compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patientsb living with moderate to severe plaque psoriasis (PsO), based on pairwise analysesc of real-world data.[1],[2] Additionally, in a post-hoc analysis of Phase 3 VOYAGE 2 clinical trial results, TREMFYA demonstrated durable clinical efficacy, itch relief and quality-of-life improvements in patients living with scal...
Source: Johnson and Johnson - March 17, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Cancer, biosimilar drug maker Coherus shedding more biotech jobs
Coherus is expected to launch a biosimilar of the rheumatoid arthritis drug Humira and recently won FDA approval of its autoinjector product for cancer patients with anemia. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 10, 2023 Category: American Health Authors: Ron Leuty Source Type: news
DNA Panels Could Predict Endoscopic Response to Biologics in CD DNA Panels Could Predict Endoscopic Response to Biologics in CD
Peripheral blood biomarkers in development that use DNA methylation could predict endoscopic response to treatment with adalimumab, vedolizumab, and ustekinumab for patients with Crohn ' s disease.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 4, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news
